HK1160841A1 - 用於治療例如癌症的疾病的取代的嘧啶 - Google Patents

用於治療例如癌症的疾病的取代的嘧啶

Info

Publication number
HK1160841A1
HK1160841A1 HK12101136.9A HK12101136A HK1160841A1 HK 1160841 A1 HK1160841 A1 HK 1160841A1 HK 12101136 A HK12101136 A HK 12101136A HK 1160841 A1 HK1160841 A1 HK 1160841A1
Authority
HK
Hong Kong
Prior art keywords
cancer
diseases
treatment
substituted pyrimidines
pyrimidines
Prior art date
Application number
HK12101136.9A
Other languages
English (en)
Inventor
Heinz Stadtmueller
Ioannis Sapountzis
Original Assignee
貝林格爾‧英格海姆國際有限公司
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Family has litigation
First worldwide family litigation filed litigation Critical https://patents.darts-ip.com/?family=42115425&utm_source=google_patent&utm_medium=platform_link&utm_campaign=public_patent_search&patent=HK1160841(A1) "Global patent litigation dataset” by Darts-ip is licensed under a Creative Commons Attribution 4.0 International License.
Application filed by 貝林格爾‧英格海姆國際有限公司 filed Critical 貝林格爾‧英格海姆國際有限公司
Publication of HK1160841A1 publication Critical patent/HK1160841A1/zh

Links

Classifications

    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07D—HETEROCYCLIC COMPOUNDS
    • C07D403/00—Heterocyclic compounds containing two or more hetero rings, having nitrogen atoms as the only ring hetero atoms, not provided for by group C07D401/00
    • C07D403/02—Heterocyclic compounds containing two or more hetero rings, having nitrogen atoms as the only ring hetero atoms, not provided for by group C07D401/00 containing two hetero rings
    • C07D403/12—Heterocyclic compounds containing two or more hetero rings, having nitrogen atoms as the only ring hetero atoms, not provided for by group C07D401/00 containing two hetero rings linked by a chain containing hetero atoms as chain links
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07D—HETEROCYCLIC COMPOUNDS
    • C07D413/00—Heterocyclic compounds containing two or more hetero rings, at least one ring having nitrogen and oxygen atoms as the only ring hetero atoms
    • C07D413/14—Heterocyclic compounds containing two or more hetero rings, at least one ring having nitrogen and oxygen atoms as the only ring hetero atoms containing three or more hetero rings
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07D—HETEROCYCLIC COMPOUNDS
    • C07D405/00—Heterocyclic compounds containing both one or more hetero rings having oxygen atoms as the only ring hetero atoms, and one or more rings having nitrogen as the only ring hetero atom
    • C07D405/14—Heterocyclic compounds containing both one or more hetero rings having oxygen atoms as the only ring hetero atoms, and one or more rings having nitrogen as the only ring hetero atom containing three or more hetero rings
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/33—Heterocyclic compounds
    • A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
    • A61K31/495—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with two or more nitrogen atoms as the only ring heteroatoms, e.g. piperazine or tetrazines
    • A61K31/505—Pyrimidines; Hydrogenated pyrimidines, e.g. trimethoprim
    • A61K31/506—Pyrimidines; Hydrogenated pyrimidines, e.g. trimethoprim not condensed and containing further heterocyclic rings
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P29/00—Non-central analgesic, antipyretic or antiinflammatory agents, e.g. antirheumatic agents; Non-steroidal antiinflammatory drugs [NSAID]
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P31/00—Antiinfectives, i.e. antibiotics, antiseptics, chemotherapeutics
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P31/00—Antiinfectives, i.e. antibiotics, antiseptics, chemotherapeutics
    • A61P31/04—Antibacterial agents
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P31/00—Antiinfectives, i.e. antibiotics, antiseptics, chemotherapeutics
    • A61P31/10—Antimycotics
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P31/00—Antiinfectives, i.e. antibiotics, antiseptics, chemotherapeutics
    • A61P31/12—Antivirals
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P35/00—Antineoplastic agents
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P35/00—Antineoplastic agents
    • A61P35/02—Antineoplastic agents specific for leukemia
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P37/00—Drugs for immunological or allergic disorders
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P37/00—Drugs for immunological or allergic disorders
    • A61P37/02—Immunomodulators
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P43/00—Drugs for specific purposes, not provided for in groups A61P1/00-A61P41/00
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07D—HETEROCYCLIC COMPOUNDS
    • C07D239/00—Heterocyclic compounds containing 1,3-diazine or hydrogenated 1,3-diazine rings
    • C07D239/02—Heterocyclic compounds containing 1,3-diazine or hydrogenated 1,3-diazine rings not condensed with other rings
    • C07D239/24—Heterocyclic compounds containing 1,3-diazine or hydrogenated 1,3-diazine rings not condensed with other rings having three or more double bonds between ring members or between ring members and non-ring members
    • C07D239/28—Heterocyclic compounds containing 1,3-diazine or hydrogenated 1,3-diazine rings not condensed with other rings having three or more double bonds between ring members or between ring members and non-ring members with hetero atoms or with carbon atoms having three bonds to hetero atoms with at the most one bond to halogen, directly attached to ring carbon atoms
    • C07D239/46—Two or more oxygen, sulphur or nitrogen atoms
    • C07D239/47—One nitrogen atom and one oxygen or sulfur atom, e.g. cytosine
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07D—HETEROCYCLIC COMPOUNDS
    • C07D401/00—Heterocyclic compounds containing two or more hetero rings, having nitrogen atoms as the only ring hetero atoms, at least one ring being a six-membered ring with only one nitrogen atom
    • C07D401/02—Heterocyclic compounds containing two or more hetero rings, having nitrogen atoms as the only ring hetero atoms, at least one ring being a six-membered ring with only one nitrogen atom containing two hetero rings
    • C07D401/12—Heterocyclic compounds containing two or more hetero rings, having nitrogen atoms as the only ring hetero atoms, at least one ring being a six-membered ring with only one nitrogen atom containing two hetero rings linked by a chain containing hetero atoms as chain links
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07D—HETEROCYCLIC COMPOUNDS
    • C07D401/00—Heterocyclic compounds containing two or more hetero rings, having nitrogen atoms as the only ring hetero atoms, at least one ring being a six-membered ring with only one nitrogen atom
    • C07D401/14—Heterocyclic compounds containing two or more hetero rings, having nitrogen atoms as the only ring hetero atoms, at least one ring being a six-membered ring with only one nitrogen atom containing three or more hetero rings
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07D—HETEROCYCLIC COMPOUNDS
    • C07D405/00—Heterocyclic compounds containing both one or more hetero rings having oxygen atoms as the only ring hetero atoms, and one or more rings having nitrogen as the only ring hetero atom
    • C07D405/02—Heterocyclic compounds containing both one or more hetero rings having oxygen atoms as the only ring hetero atoms, and one or more rings having nitrogen as the only ring hetero atom containing two hetero rings
    • C07D405/12—Heterocyclic compounds containing both one or more hetero rings having oxygen atoms as the only ring hetero atoms, and one or more rings having nitrogen as the only ring hetero atom containing two hetero rings linked by a chain containing hetero atoms as chain links
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07D—HETEROCYCLIC COMPOUNDS
    • C07D419/00—Heterocyclic compounds containing two or more hetero rings, at least one ring having nitrogen, oxygen, and sulfur atoms as the only ring hetero atoms
    • C07D419/14—Heterocyclic compounds containing two or more hetero rings, at least one ring having nitrogen, oxygen, and sulfur atoms as the only ring hetero atoms containing three or more hetero rings
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07D—HETEROCYCLIC COMPOUNDS
    • C07D493/00—Heterocyclic compounds containing oxygen atoms as the only ring hetero atoms in the condensed system
    • C07D493/02—Heterocyclic compounds containing oxygen atoms as the only ring hetero atoms in the condensed system in which the condensed system contains two hetero rings
    • C07D493/04—Ortho-condensed systems

Landscapes

  • Chemical & Material Sciences (AREA)
  • Organic Chemistry (AREA)
  • Health & Medical Sciences (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • Public Health (AREA)
  • Veterinary Medicine (AREA)
  • General Health & Medical Sciences (AREA)
  • Medicinal Chemistry (AREA)
  • Animal Behavior & Ethology (AREA)
  • Pharmacology & Pharmacy (AREA)
  • Chemical Kinetics & Catalysis (AREA)
  • Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
  • General Chemical & Material Sciences (AREA)
  • Oncology (AREA)
  • Communicable Diseases (AREA)
  • Immunology (AREA)
  • Bioinformatics & Cheminformatics (AREA)
  • Engineering & Computer Science (AREA)
  • Pain & Pain Management (AREA)
  • Rheumatology (AREA)
  • Virology (AREA)
  • Hematology (AREA)
  • Epidemiology (AREA)
  • Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
  • Plural Heterocyclic Compounds (AREA)
  • Organic Low-Molecular-Weight Compounds And Preparation Thereof (AREA)
  • Heterocyclic Carbon Compounds Containing A Hetero Ring Having Oxygen Or Sulfur (AREA)
  • Medicines That Contain Protein Lipid Enzymes And Other Medicines (AREA)
HK12101136.9A 2008-11-24 2012-02-07 用於治療例如癌症的疾病的取代的嘧啶 HK1160841A1 (zh)

Applications Claiming Priority (3)

Application Number Priority Date Filing Date Title
EP08169807 2008-11-24
EP09169654 2009-09-07
PCT/EP2009/065768 WO2010058032A2 (en) 2008-11-24 2009-11-24 New compounds

Publications (1)

Publication Number Publication Date
HK1160841A1 true HK1160841A1 (zh) 2012-08-17

Family

ID=42115425

Family Applications (1)

Application Number Title Priority Date Filing Date
HK12101136.9A HK1160841A1 (zh) 2008-11-24 2012-02-07 用於治療例如癌症的疾病的取代的嘧啶

Country Status (27)

Country Link
US (4) US8846689B2 (zh)
EP (1) EP2367800B9 (zh)
JP (1) JP5622740B2 (zh)
KR (1) KR101710058B1 (zh)
CN (2) CN104478865B (zh)
AP (1) AP2960A (zh)
AR (1) AR074210A1 (zh)
AU (1) AU2009317170B2 (zh)
BR (1) BRPI0922801B1 (zh)
CA (1) CA2744351C (zh)
CL (1) CL2011001215A1 (zh)
CO (1) CO6511283A2 (zh)
EA (1) EA021997B1 (zh)
EC (1) ECSP11011079A (zh)
ES (1) ES2664499T3 (zh)
GE (1) GEP20146072B (zh)
HK (1) HK1160841A1 (zh)
IL (1) IL212814B (zh)
MA (1) MA32811B1 (zh)
MX (1) MX337116B (zh)
MY (1) MY176944A (zh)
NZ (1) NZ592925A (zh)
PE (1) PE20120034A1 (zh)
TN (1) TN2011000259A1 (zh)
TW (1) TWI491605B (zh)
UY (1) UY32259A (zh)
WO (1) WO2010058032A2 (zh)

Families Citing this family (26)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
TW201024281A (en) 2008-11-24 2010-07-01 Boehringer Ingelheim Int New compounds
TWI491605B (zh) 2008-11-24 2015-07-11 Boehringer Ingelheim Int 新穎化合物
US8933227B2 (en) 2009-08-14 2015-01-13 Boehringer Ingelheim International Gmbh Selective synthesis of functionalized pyrimidines
US8729265B2 (en) 2009-08-14 2014-05-20 Boehringer Ingelheim International Gmbh Regioselective preparation of 2-amino-5-trifluoromethylpyrimidine derivatives
US20120244141A1 (en) 2010-09-28 2012-09-27 Boehringer Ingelheim International Gmbh Stratification of cancer patients for susceptibility to therapy with PTK2 inhibitors
DK2675793T3 (en) * 2011-02-17 2018-11-12 Cancer Therapeutics Crc Pty Ltd FAK INHIBITORS
CA2827172C (en) 2011-02-17 2019-02-26 Cancer Therapeutics Crc Pty Limited Selective fak inhibitors
EP2832734A4 (en) * 2012-03-28 2015-08-26 Takeda Pharmaceutical HETEROCYCLIC CONNECTION
BR112016005262B1 (pt) 2013-09-09 2021-11-30 Peloton Therapeutics, Inc Compostos aril éteres, uso dos mesmos e composição farmacêutica que os compreende
EP3267792A4 (en) 2015-03-11 2018-09-26 Peloton Therapeutics, Inc. Compositions for use in treating pulmonary arterial hypertension
WO2016145045A1 (en) 2015-03-11 2016-09-15 Peloton Therapeutics, Inc. Compositions for use in treating glioblastoma
US10155726B2 (en) 2015-03-11 2018-12-18 Peloton Therapeutics, Inc. Substituted pyridines and uses thereof
US10807948B2 (en) 2015-03-11 2020-10-20 Peloton Therapeutics, Inc. Aromatic compounds and uses thereof
WO2016168510A1 (en) 2015-04-17 2016-10-20 Peloton Therapeutics, Inc. Combination therapy of a hif-2-alpha inhibitor and an immunotherapeutic agent and uses thereof
US20170066778A1 (en) * 2015-09-04 2017-03-09 Aunova Medchem LLC Solubility for target compounds
JP2023503897A (ja) 2019-11-18 2023-02-01 ▲應▼世生物科技（南京）有限公司 Ｎｒａｓ変異を有する腫瘍を治療するための医薬品の調製におけるｆａｋ阻害剤の使用
JP2023504460A (ja) * 2019-11-28 2023-02-03 ▲應▼世生物科技（南京）有限公司 癌の治療におけるｂｉ８５３５２０の使用
WO2021155764A1 (zh) 2020-02-05 2021-08-12 应世生物科技(南京)有限公司 Bi853520与化疗药物的联用
EP4190774A4 (en) * 2020-08-03 2024-01-17 Inxmed (Nanjing) Co., Ltd. SOLID FORM OF COMPOUND
TW202313044A (zh) * 2021-08-16 2023-04-01 大陸商應世生物科技（南京）有限公司 Ｉｎ１００１８與ｐｌｄ的聯用
TW202339755A (zh) 2021-12-10 2023-10-16 大陸商應世生物科技（南京）有限公司 治療腫瘤的藥物組合及用途
WO2023116527A1 (zh) 2021-12-21 2023-06-29 微境生物医药科技(上海)有限公司 作为fak抑制剂的化合物及其用途
WO2023160614A1 (zh) * 2022-02-28 2023-08-31 微境生物医药科技(上海)有限公司 作为fak抑制剂的化合物及其用途
TW202408528A (zh) 2022-06-24 2024-03-01 大陸商應世生物科技（南京）有限公司 治療腫瘤的藥物組合及用途
CN117462553A (zh) * 2022-07-20 2024-01-30 益方生物科技(上海)股份有限公司 药物组合产品以及组合疗法
WO2024041527A1 (zh) * 2022-08-24 2024-02-29 应世生物科技(南京)有限公司 Fak抑制剂及微管抑制剂的药物组合及用途

Family Cites Families (37)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
GB9705361D0 (en) * 1997-03-14 1997-04-30 Celltech Therapeutics Ltd Chemical compounds
DE69933680T2 (de) 1998-08-29 2007-08-23 Astrazeneca Ab Pyrimidine verbindungen
US6906067B2 (en) * 1999-12-28 2005-06-14 Bristol-Myers Squibb Company N-heterocyclic inhibitors of TNF-α expression
GB0004890D0 (en) * 2000-03-01 2000-04-19 Astrazeneca Uk Ltd Chemical compounds
GB0004886D0 (en) 2000-03-01 2000-04-19 Astrazeneca Uk Ltd Chemical compounds
GB0004888D0 (en) * 2000-03-01 2000-04-19 Astrazeneca Uk Ltd Chemical compounds
GB0016877D0 (en) 2000-07-11 2000-08-30 Astrazeneca Ab Chemical compounds
UY27487A1 (es) 2001-10-17 2003-05-30 Boehringer Ingelheim Pharma Derivados de pirimidina, medicamentos que contienen estos compuestos, su empleo y procedimiento para su preparación
MY141867A (en) 2002-06-20 2010-07-16 Vertex Pharma Substituted pyrimidines useful as protein kinase inhibitors
CN1717396A (zh) 2002-11-28 2006-01-04 舍林股份公司 Chk－、Pdk－和Akt－抑制嘧啶,其制备及作为药物的用途
CL2004000303A1 (es) * 2003-02-20 2005-04-08 Tibotec Pharm Ltd Compuestos derivados de pirimidinas y triazinas; proceso de preparacion; composicion farmaceutica; y su uso para inhibir la replicacion del vih.
ES2325440T3 (es) 2003-02-20 2009-09-04 Smithkline Beecham Corporation Compuestos de pirimidina.
GB0305929D0 (en) 2003-03-14 2003-04-23 Novartis Ag Organic compounds
US7504396B2 (en) * 2003-06-24 2009-03-17 Amgen Inc. Substituted heterocyclic compounds and methods of use
PL2287156T3 (pl) 2003-08-15 2013-11-29 Novartis Ag 2,4-Di(fenyloamino)-pirymidyny stosowane w leczeniu chorób nowotworowych, chorób zapalnych i zaburzeń układu immunologicznego
EP1598343A1 (de) 2004-05-19 2005-11-23 Boehringer Ingelheim International GmbH 2-Arylaminopyrimidine als PLK Inhibitoren
US7521457B2 (en) * 2004-08-20 2009-04-21 Boehringer Ingelheim International Gmbh Pyrimidines as PLK inhibitors
GB0419160D0 (en) * 2004-08-27 2004-09-29 Novartis Ag Organic compounds
TW200626560A (en) 2004-09-30 2006-08-01 Tibotec Pharm Ltd HIV inhibiting 5-carbo-or heterocyclic substituted pyrimidines
AU2006204752A1 (en) 2005-01-14 2006-07-20 Neurogen Corporation Heteroaryl substituted quinolin-4-ylamine analogues
US20070032514A1 (en) 2005-07-01 2007-02-08 Zahn Stephan K 2,4-diamino-pyrimidines as aurora inhibitors
EP1934200A1 (en) * 2005-09-15 2008-06-25 Merck & Co., Inc. Tyrosine kinase inhibitors
US20080318989A1 (en) * 2005-12-19 2008-12-25 Burdick Daniel J Pyrimidine Kinase Inhibitors
FR2896503B1 (fr) 2006-01-23 2012-07-13 Aventis Pharma Sa Nouveaux derives soufres d'uree cyclique, leur preparation et leur utilisation pharmaceutique comme inhibiteurs de kinases
TW200804364A (en) 2006-02-22 2008-01-16 Boehringer Ingelheim Int New compounds
US7507737B2 (en) 2006-03-31 2009-03-24 Janssen Pharmaceutica, N.V. Benzoimidazol-2-yl pyrimidines and pyrazines as modulators of the histamine H4receptor
GB0619343D0 (en) 2006-09-30 2006-11-08 Vernalis R&D Ltd New chemical compounds
WO2008040951A1 (en) 2006-10-03 2008-04-10 Astrazeneca Ab Compounds
AU2007332654B2 (en) 2006-12-13 2013-06-20 F. Hoffmann-La Roche Ag 2-(piperidin-4-yl)-4-phenoxy- or phenylamino-pyrimidine derivatives as non-nucleoside reverse transcriptase inhibitors
EP2099771A1 (en) * 2006-12-19 2009-09-16 Genentech, Inc. Pyrimidine kinase inhibitors
EP2114900B1 (en) * 2007-01-31 2018-10-10 YM BioSciences Australia Pty Ltd Thiopyrimidine-based compounds and uses thereof
CA2684470C (en) * 2007-04-16 2016-02-09 Hutchison Medipharma Enterprises Limited Pyrimidine derivatives
WO2009115583A1 (en) 2008-03-20 2009-09-24 Boehringer Ingelheim International Gmbh Regioselective preparation of substituted pyrimidines
AU2009262068C1 (en) 2008-06-27 2015-07-02 Celgene Car Llc Heteroaryl compounds and uses thereof
TW201024281A (en) 2008-11-24 2010-07-01 Boehringer Ingelheim Int New compounds
TWI491605B (zh) 2008-11-24 2015-07-11 Boehringer Ingelheim Int 新穎化合物
WO2010129053A2 (en) 2009-05-05 2010-11-11 Dana Farber Cancer Institute Egfr inhibitors and methods of treating disorders

Also Published As

Publication number Publication date
AU2009317170A1 (en) 2010-05-27
MX2011005420A (es) 2011-06-16
KR20110084551A (ko) 2011-07-25
MX337116B (es) 2016-02-12
EP2367800B1 (en) 2018-02-28
AP2011005706A0 (en) 2011-06-30
TN2011000259A1 (en) 2012-12-17
ECSP11011079A (es) 2011-06-30
CN102292322B (zh) 2015-11-25
MA32811B1 (fr) 2011-11-01
AP2960A (en) 2014-08-31
BRPI0922801B1 (pt) 2021-12-21
PE20120034A1 (es) 2012-02-19
ES2664499T3 (es) 2018-04-19
JP5622740B2 (ja) 2014-11-12
US20110288071A1 (en) 2011-11-24
UY32259A (es) 2010-06-30
TW201026682A (en) 2010-07-16
WO2010058032A2 (en) 2010-05-27
CN104478865B (zh) 2017-09-22
CN104478865A (zh) 2015-04-01
US20140371205A1 (en) 2014-12-18
IL212814A0 (en) 2011-07-31
BRPI0922801A2 (pt) 2020-08-04
AR074210A1 (es) 2010-12-29
TWI491605B (zh) 2015-07-11
US20160362404A1 (en) 2016-12-15
KR101710058B1 (ko) 2017-02-24
CA2744351C (en) 2017-07-04
AU2009317170B2 (en) 2015-05-28
EA021997B1 (ru) 2015-10-30
EP2367800B9 (en) 2021-10-20
EP2367800A2 (en) 2011-09-28
NZ592925A (en) 2013-04-26
US8846689B2 (en) 2014-09-30
CO6511283A2 (es) 2012-08-31
GEP20146072B (en) 2014-04-10
US9676762B2 (en) 2017-06-13
EA201100794A1 (ru) 2012-01-30
CL2011001215A1 (es) 2011-09-30
JP2012509864A (ja) 2012-04-26
IL212814B (en) 2018-05-31
CA2744351A1 (en) 2010-05-27
ES2664499T9 (es) 2022-01-03
US20150376141A1 (en) 2015-12-31
MY176944A (en) 2020-08-27
WO2010058032A3 (en) 2010-07-15
CN102292322A (zh) 2011-12-21

Similar Documents

Publication Publication Date Title
AP2960A (en) Substituted pyrimidines for the treatment of diseases such as cancer
IL214746A0 (en) Substituted pyrimidines for the treatment of cancer
LT2303021T (lt) Junginiai, skirti vėžio gydymui
HK1154382A1 (en) Triazole derivatives useful for the treatment of diseases
IL200862A0 (en) 3-imidazolyl-indoles for the treatment of proliferative diseases
EP2365815A4 (en) EXTRACELLULAR MATRIX COMPOSITIONS FOR THE TREATMENT OF CANCER
ZA201101899B (en) Bicyclic triazole derivatives for the treatment of tumours
IL208357A0 (en) Spiro-indole derivatives for the treatment of parasitic diseases
ZA201107879B (en) Composition for the treatment of prostate cancer
IL213761A0 (en) Novel ortho-aminoamides for the treatment of cancer
EP2331520A4 (en) ROSAMINE DERIVATIVES AS AGENTS FOR CANCER TREATMENT
ZA201003425B (en) 5-cyano-thienopyridines for the treatment of tumors
IL201449A0 (en) Heteroarylamide-substituted pyrimidone derivatives for the treatment of neurodegenerative diseases
IL210066A0 (en) Novel ortho-aminoanilides for the treatment of cancer
EP2331130A4 (en) IGE ANTIBODIES FOR THE TREATMENT OF CANCER
IL220134A0 (en) Thiazole derivatives for the treatment of diseases such as cancer
IL209005A0 (en) Use of corticotropin-releasing factor for the treatment of cancer
AP2011005893A0 (en) Thia-triaza-cyclopentazulenes as P13-kinases inhibitors for the treatment of cancer.
EP2214485A4 (en) METHOD FOR THE TREATMENT OF CANCER
GB0712513D0 (en) Treatment of cancer
GB0817056D0 (en) Polypeptide for treatment of cancer
GB0604114D0 (en) Combinations for the treatment of cancer